PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions

Footnotes and References

a.assessment based on product information accessed via the Therapeutic Goods Administration of Australia Product and Consumer Medicines Information website ( https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=PI&q=&r=https://www.ebs.tga.gov.au/ ).
b.reported at Clinical Trials.gov ( http://clinicaltrials.gov/ct2/show/study/NCT00785486?sect=X701&view=results ).
1.Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and cypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clinical Pharmacology & Therapeutics 2004; 76: 598-606.[PubMed]
2.Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ. Fluvoxamine Drastically Increases Concentrations and Effects of Tizanidine: A Potentially Hazardous Interaction. Clinical Pharmacology & Therapeutics 2004; 75: 331-41.[PubMed]
3.Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharmaceutics & Drug Disposition 2002; 23: 77-81.[PubMed]
4.Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. British Journal of Clinical Pharmacology 2004; 57: 487-94.[PubMed]
5.Ieiri I, Kimura M, He S, Urae A, Otsubo K, Ishizaki T. Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. Pharmacogenetics and Genomics 2005; 15: 851-59.[PubMed]
6.Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clinical Pharmacology & Therapeutics 1998; 64: 133-43.[PubMed]
7.Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clinical Pharmacology & Therapeutics 1997; 62: 348-54.[PubMed]
8.Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clinical Pharmacology & Therapeutics 1998; 64: 655-60.[PubMed]
9.Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology & Therapeutics 1994; 55: 481-85.[PubMed]
10.Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJJ, Klein CE, Rublein JC, Kashuba ADM. Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes 2006; 42: 52-60.[PubMed]
11.Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir. Clinical Pharmacology & Therapeutics 2006; 79: 243-54.[PubMed]
12.Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clinical Pharmacology & Therapeutics 1999; 66: 33-39.[PubMed]
13.Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 27-37.[PubMed]
14.Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clinical Pharmacology & Therapeutics 2006; 79: 362-70.[PubMed]
15.Wietholtz H, Zysset T, Kreiten K, Kohl D, Buchsel R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. European Journal of Clinical Pharmacology 1989; 36: 401-06.[PubMed]
16.Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. European Journal of Clinical Pharmacology 2006; 62: 451-61.[PubMed]
17.Adams M, Pieniaszek HJ, Gammaitoni AR, Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. Journal of Clinical Pharmacology 2005; 45: 337-45.[PubMed]
18.Haas CE, Brazeau D, Cloen D, Booker BM, Frerichs V, Zaranek C, Frye RF, Kufel T. Cytochrome P-450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. European Journal of Clinical Pharmacology 2005; 61: 583-93.[PubMed]
19.Wang LS, Zhou G, Zhu B, Wu J, Wang JG, El-Aty AMA, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clinical Pharmacology & Therapeutics 2004; 75: 191-97.[PubMed]
20.Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjorndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. European Journal of Clinical Pharmacology 2004; 59: 879-82.[PubMed]
21.Robertson P, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clinical Pharmacology & Therapeutics 2002; 71: 46-56.[PubMed]
22.Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253-57.[PubMed]
23.Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clinical Pharmacology & Therapeutics 1996; 59: 7-13.[PubMed]
24.Wang ZQ, Gorski C, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology & Therapeutics 2001; 70: 317-26.[PubMed]
25.Malmstrom K, Schwartz J, Reiss TF, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Shingo S, Peszek I, Larson P, Ebel D, Hunt TL, Huhn RD, Bachmann K. Effect of Montelukast on Single-Dose Theophylline Pharmacokinetics. American Journal of Therapeutics 1998; 5: 189-96.[PubMed]
26.Saccar CL, Danish M, Ragni MC, Rocci ML, Greene J, Yaffe SJ, Mansmann HC. The effect of phenobarbital on theophylline disposition in children with asthma. Journal of Allergy and Clinical Immunology 1985; 75: 716-19.[PubMed]
27.Backman JT, Schroder MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. European Journal of Clinical Pharmacology 2008; 64: 17-24.[PubMed]
28.Lai ML, Lin TS, Huang JD. Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. European Journal of Clinical Pharmacology 1992; 43: 201-03.[PubMed]
29.Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clinical Pharmacology & Therapeutics 2003; 73: 264-71.[PubMed]
30.Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-50.[PubMed]
31.Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blu RA. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. Journal of Clinical Pharmacology 2004; 44: 215-23.[PubMed]
32.Dingemanse J, Schaarschmidt D, van Giersbergen PLM. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clinical Pharmacokinetics 2003; 42: 293-301.[PubMed]
33.Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 1998; 83: 135-38.[PubMed]
34.Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolarn and fexofenadine pharmacokinetics in healthy subjects. Current Medical Research and Opinion 2008; 24: 591-99.[PubMed]
35.Ochs HR, Greenblatt DJ, Burstein ES. Lack of influence of cigarette smoking on triazolam pharmacokinetics. British Journal of Clinical Pharmacology 1987; 23: 759-63.[PubMed]
36.Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. British Journal of Clinical Pharmacology 1995; 40: 270-72.[PubMed]
Disclaimer
WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.